🇺🇸 FDA
Patent

US 10588940

Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

granted A61KA61K38/1891A61P

Quick answer

US patent 10588940 (Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/1891, A61P, A61P7/04